Answers are grounded in this paper and cite their sources.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) drives low-density lipoprotein receptor (LDLR) degradation, making its targeted inhibition a cornerstone of atherosclerosis management. Here, we develop an Ultrasound/Nanodroplet-Enabled PCSK9 (UNEP) vaccine platform for efficient PCSK9 blockade. To establish an immunocompetent microenvironment, an injectable hydrogel, co-loaded with granulocyte-macrophage colony-stimulating factor (GM-CSF) and STING agonist-encapsulating extracellular vesicles (EVs), is utilized to recruit and activate dendritic cells (DCs), forming a hydrogel-based immune niche. Subsequent administration of PCSK9 antigen-loaded phase-transition nanodroplets (NDs) into this depot, coupled with targeted ultrasound irradiation, achieves spatiotemporal and efficiently delivery of the antigen. Consequently, the UNEP vaccine elicits robust and durable anti-PCSK9 immunity, sustaining high antigen-specific IgG titers for over four weeks. In ApoE −/− mice, this strategy effectively neutralized PCSK9, restored hepatic LDLR expression, and led to a significant reduction in aortic atherosclerotic plaque burden. By synergistically integrating hydrogel biomaterials, EV-based adjuvants, and ultrasound-responsive nanotechnology, this platform provides a highly versatile paradigm for precision vaccination.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: